panvax h1n1 vaccine, h1n1 pandemic influenza vaccine (split-virion, inactivated) 5ml multi-dose injection vial
seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate; thiomersal - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.
panvax h1n1 vaccine, h1n1 pandemic influenza vaccine (split-virion, inactivated) 0.5ml injection pre-filled syringe
seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.
panvax h1n1 vaccine, h1n1 pandemic influenza vaccine (split-virion, inactivated) 10ml multi-dose injection vial
seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate; thiomersal - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.
pandemic influenza vaccine h5n1 baxter ag
resilience biomanufacturing ireland limited - influenza vaccine (whole virion, inactivated) containing antigen of: a/vietnam/1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.
bulk quadrivalent influenza vaccine (split virion, inactivated)
seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram/ml - injection, suspension - excipient ingredients: dibasic sodium phosphate; water for injections; monobasic potassium phosphate; sodium chloride; potassium chloride; calcium chloride dihydrate; monobasic sodium phosphate - for active immunization against influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine.
fluquadri junior inactivated quadrivalent influenza vaccine (split virion), influenza virus haemagglutinin 30mcg, 0.25ml suspens
sanofi-aventis australia pty ltd - influenza virus haemagglutinin -
fluquadri inactivated quadrivalent influenza vaccine (split virion), influenza virus haemagglutinin 60mcg, 0.5ml suspension for injection
sanofi-aventis australia pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; monobasic sodium phosphate; octoxinol 9; dibasic sodium phosphate - fluquadri is indicated for active immunisation of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine.,fluquadri is indicated for use in adults and children 6 months and older.
influenza a- h1n1 2009 monovalent vaccine injection, suspension
novartis vaccines and diagnostics ltd - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) (unii: k9p8pva2ug) (influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) - unii:k9p8pva2ug) - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) 15 ug in 0.5 ml - influenza a (h1n1) 2009 monovalent vaccine is an inactivated influenza virus vaccine indicated for immunization of persons 4 years of age and older against influenza disease caused by pandemic (h1n1) 2009 virus. influenza a (h1n1) 2009 monovalent vaccine should not be administered to anyone with known systemic hypersensitivity reactions to egg proteins (eggs or egg products), or to any component of influenza a (h1n1) 2009 monovalent vaccine, or who has had a life-threatening reaction to previous influenza vaccinations [see description (11)]. novartis’ influenza a (h1n1) 2009 monovalent vaccine and seasonal trivalent influenza virus vaccine (fluvirin) are manufactured by the same process. available information for fluvirin is provided in this section. pregnancy category c: animal reproduction studies have not been conducted with influenza a (h1n1) 2009 monovalent vaccine or fluvirin. it is also not known whether influenza a (h1n1) 2009 monovalent vaccine or fluvirin can cause fetal harm when administered to
fluarix tetra susp for inj in pre-filled syringe / influenza vaccine (split viron, inactivated)
glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - a, brisbane, h, ivr, kansas, nymc x, phuket, wild type, nymc bx - suspension for injection in pre-filled syringe - a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227 15 µg b/phuket/3073/2013 - like strain (b/phuket/3073/2013, wild type) 15 µg b/austria/1359417/2021 - like strain (b/austria/1359417/2021 bvr-26 15 µg a/victoria/4897/2022 (h1n1) pdm09 - like strain (a/victoria/4897/2022 ivr-238 15 µg - vaccines
vaxigrip vaccine
sanofi-aventis new zealand limited - influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/ hong kong/4801/2014 nymc x-263b ); ; influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/michigan/45/2015 nymc x-275); ; influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/60/2008 ); - solution for injection - 0.5 ml - active: influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/ hong kong/4801/2014 nymc x-263b ) influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/michigan/45/2015 nymc x-275) influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/60/2008 ) excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin potassium chloride sodium chloride water for injection - vaxigrip is indicated for the prevention of influenza caused by influenza virus types a and b in adults and children aged 6 months and over.